$0.99
+0.04 (+4.11%)
Open$0.96
Previous Close$0.95
Day High$1.02
Day Low$0.95
52W High$39.87
52W Low$20.28
Volume—
Avg Volume75.6K
Market Cap36.28M
P/E Ratio39.10
EPS$0.76
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+3,682.8% upside
Current
$0.99
$0.99
Target
$37.45
$37.45
$24.30
$37.45 avg
$44.03
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.79M | 3.81M | 2.96M |
| Net Income | 783.4K | 928.9K | 608.3K |
| Profit Margin | 20.7% | 24.4% | 20.5% |
| EBITDA | 1.80M | 1.92M | 1.50M |
| Free Cash Flow | 820.9K | 949.0K | 713.4K |
| Rev Growth | +6.9% | +13.5% | +17.7% |
| Debt/Equity | 0.92 | 0.74 | 0.98 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |